CG Oncology Director Cuts Stake by $1.14M After Option Exercise
James Mulay, a director at CG Oncology, disposed of 15,600 common shares on April 17, 2026, through a pre-arranged Rule 10b5-1 plan. The sale, executed at a weighted average price of $73.01, generated proceeds of $1,138,956. Mulay had earlier acquired the same shares by exercising vested director stock options at $36.63 per share. The transaction l…